Mark Levine
Concepts (436)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ascorbic Acid | 50 | 2025 | 180 | 11.420 |
Why?
| | Erythrocyte Deformability | 4 | 2024 | 23 | 2.100 |
Why?
| | Erythrocytes | 7 | 2024 | 757 | 1.800 |
Why?
| | Vitamins | 8 | 2023 | 178 | 1.670 |
Why?
| | Vitamin E | 4 | 2020 | 121 | 1.600 |
Why?
| | Anemia, Sickle Cell | 4 | 2023 | 312 | 1.470 |
Why?
| | Antioxidants | 8 | 2020 | 549 | 1.240 |
Why?
| | Dehydroascorbic Acid | 5 | 2025 | 6 | 1.230 |
Why?
| | Organic Anion Transporters, Sodium-Dependent | 8 | 2010 | 14 | 1.020 |
Why?
| | Ascorbic Acid Deficiency | 2 | 2023 | 10 | 0.990 |
Why?
| | Symporters | 8 | 2010 | 48 | 0.990 |
Why?
| | Hydrogen Peroxide | 7 | 2024 | 336 | 0.900 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1958 | 0.860 |
Why?
| | Antineoplastic Agents | 6 | 2020 | 2197 | 0.850 |
Why?
| | Sodium-Coupled Vitamin C Transporters | 9 | 2016 | 9 | 0.820 |
Why?
| | Osmotic Fragility | 3 | 2024 | 12 | 0.820 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 53 | 0.810 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 102 | 0.790 |
Why?
| | Fabry Disease | 1 | 2023 | 2 | 0.780 |
Why?
| | Pancreatic Neoplasms | 5 | 2024 | 927 | 0.740 |
Why?
| | Quarantine | 2 | 2021 | 31 | 0.720 |
Why?
| | Contact Tracing | 2 | 2021 | 26 | 0.710 |
Why?
| | Prodrugs | 3 | 2024 | 52 | 0.690 |
Why?
| | Glucose Transporter Type 2 | 3 | 2013 | 16 | 0.690 |
Why?
| | Glucose | 8 | 2022 | 1049 | 0.680 |
Why?
| | Neoplasms | 8 | 2022 | 2884 | 0.660 |
Why?
| | Glucose Transport Proteins, Facilitative | 4 | 2017 | 16 | 0.650 |
Why?
| | Thiamine | 4 | 2021 | 18 | 0.630 |
Why?
| | Tobacco Products | 1 | 2020 | 84 | 0.590 |
Why?
| | Hydrocortisone | 5 | 2021 | 304 | 0.590 |
Why?
| | Dietary Supplements | 2 | 2016 | 576 | 0.580 |
Why?
| | Kidney | 4 | 2023 | 1496 | 0.580 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 292 | 0.580 |
Why?
| | Oxidation-Reduction | 5 | 2025 | 1087 | 0.560 |
Why?
| | Diabetic Nephropathies | 1 | 2022 | 318 | 0.560 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2020 | 108 | 0.560 |
Why?
| | Vitamin B Complex | 2 | 2020 | 40 | 0.530 |
Why?
| | Dietary Fats | 1 | 2019 | 315 | 0.520 |
Why?
| | Fetal Hemoglobin | 1 | 2017 | 8 | 0.520 |
Why?
| | Hemoglobin, Sickle | 1 | 2017 | 19 | 0.520 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1098 | 0.510 |
Why?
| | Fatty Liver | 1 | 2020 | 251 | 0.510 |
Why?
| | Humans | 68 | 2025 | 144957 | 0.510 |
Why?
| | Scurvy | 2 | 2022 | 17 | 0.490 |
Why?
| | Gelatin | 1 | 2016 | 56 | 0.480 |
Why?
| | Stromal Cells | 1 | 2016 | 125 | 0.480 |
Why?
| | Embryo, Mammalian | 1 | 2016 | 232 | 0.470 |
Why?
| | Biological Transport | 6 | 2017 | 418 | 0.460 |
Why?
| | Iron | 2 | 2020 | 359 | 0.450 |
Why?
| | Mice | 22 | 2024 | 18365 | 0.440 |
Why?
| | Monosaccharide Transport Proteins | 3 | 2004 | 56 | 0.440 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2024 | 930 | 0.430 |
Why?
| | Melanoma, Experimental | 1 | 2015 | 108 | 0.430 |
Why?
| | Complementary Therapies | 2 | 2017 | 94 | 0.420 |
Why?
| | Flavonoids | 2 | 2006 | 87 | 0.410 |
Why?
| | Administration, Intravenous | 4 | 2024 | 170 | 0.410 |
Why?
| | Vermont | 4 | 2021 | 13 | 0.410 |
Why?
| | HIV Infections | 2 | 2023 | 3154 | 0.400 |
Why?
| | Sepsis | 4 | 2021 | 641 | 0.400 |
Why?
| | Animals | 29 | 2024 | 38109 | 0.390 |
Why?
| | Mice, Knockout | 7 | 2017 | 3125 | 0.380 |
Why?
| | Cross-Sectional Studies | 5 | 2024 | 5872 | 0.370 |
Why?
| | Ethics, Medical | 3 | 2021 | 90 | 0.360 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2016 | 906 | 0.360 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2012 | 598 | 0.360 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 278 | 0.340 |
Why?
| | Fructose | 3 | 2013 | 130 | 0.340 |
Why?
| | Male | 25 | 2024 | 72406 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 2584 | 0.330 |
Why?
| | Perinatal Mortality | 1 | 2010 | 21 | 0.320 |
Why?
| | Female | 30 | 2024 | 78376 | 0.310 |
Why?
| | Intestinal Mucosa | 2 | 2013 | 676 | 0.290 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 695 | 0.270 |
Why?
| | Capital Punishment | 1 | 2008 | 4 | 0.270 |
Why?
| | Oxidants | 1 | 2008 | 103 | 0.270 |
Why?
| | Kinetics | 4 | 2020 | 1629 | 0.270 |
Why?
| | Hyperaldosteronism | 1 | 2007 | 12 | 0.260 |
Why?
| | Extracellular Fluid | 1 | 2007 | 37 | 0.260 |
Why?
| | Adrenal Glands | 1 | 2007 | 77 | 0.250 |
Why?
| | Oocytes | 5 | 2013 | 178 | 0.250 |
Why?
| | Physician's Role | 2 | 2008 | 220 | 0.250 |
Why?
| | Anti-Inflammatory Agents | 2 | 2021 | 475 | 0.250 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 147 | 0.250 |
Why?
| | Adult | 13 | 2024 | 40506 | 0.240 |
Why?
| | Infusions, Intravenous | 4 | 2022 | 423 | 0.240 |
Why?
| | Health Care Reform | 1 | 2007 | 110 | 0.240 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2012 | 2032 | 0.240 |
Why?
| | Apoptosis | 4 | 2020 | 2430 | 0.230 |
Why?
| | Double-Blind Method | 4 | 2024 | 2029 | 0.230 |
Why?
| | Middle Aged | 12 | 2024 | 35928 | 0.230 |
Why?
| | Consensus | 1 | 2007 | 489 | 0.220 |
Why?
| | Rats | 6 | 2016 | 5614 | 0.220 |
Why?
| | Lymphoma, B-Cell | 1 | 2006 | 132 | 0.220 |
Why?
| | Sodium | 2 | 2004 | 197 | 0.220 |
Why?
| | Reactive Oxygen Species | 3 | 2020 | 621 | 0.210 |
Why?
| | Quercetin | 3 | 2013 | 18 | 0.210 |
Why?
| | Aged | 8 | 2024 | 25947 | 0.200 |
Why?
| | Public Policy | 2 | 2021 | 79 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 234 | 0.200 |
Why?
| | Erythrocytes, Abnormal | 1 | 2023 | 14 | 0.190 |
Why?
| | Mustelidae | 1 | 2022 | 2 | 0.190 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2006 | 259 | 0.190 |
Why?
| | Lymphoma | 2 | 2020 | 233 | 0.190 |
Why?
| | Deoxycytidine | 3 | 2017 | 221 | 0.190 |
Why?
| | Diabetic Angiopathies | 1 | 2024 | 263 | 0.190 |
Why?
| | Sample Size | 2 | 2019 | 123 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2020 | 75 | 0.180 |
Why?
| | Actins | 1 | 2024 | 425 | 0.180 |
Why?
| | HIV | 1 | 2023 | 250 | 0.180 |
Why?
| | Physicians | 2 | 2021 | 940 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 359 | 0.180 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 412 | 0.170 |
Why?
| | Xenopus laevis | 4 | 2006 | 105 | 0.170 |
Why?
| | Flow Cytometry | 1 | 2025 | 1173 | 0.170 |
Why?
| | Sleep Medicine Specialty | 1 | 2021 | 10 | 0.170 |
Why?
| | Blood Platelets | 1 | 2024 | 400 | 0.170 |
Why?
| | Iron, Dietary | 1 | 2021 | 23 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2147 | 0.160 |
Why?
| | Holocaust | 1 | 2021 | 16 | 0.160 |
Why?
| | Absorption | 2 | 2011 | 60 | 0.160 |
Why?
| | Bioethics | 1 | 2021 | 25 | 0.160 |
Why?
| | DNA Damage | 3 | 2020 | 430 | 0.160 |
Why?
| | World Health Organization | 1 | 2020 | 105 | 0.160 |
Why?
| | Students, Health Occupations | 1 | 2021 | 37 | 0.160 |
Why?
| | Anesthesiologists | 1 | 2021 | 67 | 0.160 |
Why?
| | Masks | 1 | 2021 | 70 | 0.160 |
Why?
| | Mice, Nude | 4 | 2024 | 688 | 0.160 |
Why?
| | alpha-Tocopherol | 1 | 2020 | 32 | 0.150 |
Why?
| | Cell Line, Tumor | 6 | 2024 | 3550 | 0.150 |
Why?
| | Succinate Dehydrogenase | 1 | 2020 | 67 | 0.150 |
Why?
| | Housing | 1 | 2021 | 144 | 0.150 |
Why?
| | Drug Synergism | 4 | 2020 | 357 | 0.150 |
Why?
| | Cell Death | 2 | 2013 | 383 | 0.150 |
Why?
| | Tobacco Use | 1 | 2020 | 61 | 0.150 |
Why?
| | Public Health Practice | 1 | 2020 | 63 | 0.150 |
Why?
| | Liver | 3 | 2020 | 1888 | 0.150 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2540 | 0.150 |
Why?
| | Pheochromocytoma | 1 | 2020 | 67 | 0.150 |
Why?
| | Young Adult | 4 | 2021 | 14126 | 0.150 |
Why?
| | Infection Control | 1 | 2021 | 172 | 0.150 |
Why?
| | Proteins | 2 | 2003 | 1022 | 0.150 |
Why?
| | Nutrition Policy | 2 | 2009 | 58 | 0.150 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 760 | 0.150 |
Why?
| | Deuterium | 1 | 2019 | 100 | 0.150 |
Why?
| | Lyme Disease | 1 | 2019 | 58 | 0.140 |
Why?
| | Employment | 1 | 2021 | 188 | 0.140 |
Why?
| | Hepacivirus | 1 | 2020 | 243 | 0.140 |
Why?
| | Health Services Accessibility | 1 | 2007 | 1099 | 0.140 |
Why?
| | DNA Demethylation | 1 | 2018 | 4 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2021 | 268 | 0.140 |
Why?
| | Biological Availability | 2 | 2013 | 142 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2024 | 3608 | 0.140 |
Why?
| | Lipoproteins | 1 | 2020 | 169 | 0.140 |
Why?
| | Myocarditis | 1 | 2019 | 102 | 0.140 |
Why?
| | Comorbidity | 1 | 2023 | 1660 | 0.140 |
Why?
| | Mixed Function Oxygenases | 1 | 2018 | 49 | 0.140 |
Why?
| | Genomics | 2 | 2023 | 836 | 0.140 |
Why?
| | United States | 11 | 2021 | 15988 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2019 | 1721 | 0.140 |
Why?
| | Anesthesiology | 1 | 2021 | 175 | 0.140 |
Why?
| | Meals | 1 | 2019 | 130 | 0.140 |
Why?
| | Blood Viscosity | 1 | 2018 | 18 | 0.140 |
Why?
| | Universities | 1 | 2021 | 452 | 0.140 |
Why?
| | Oxidative Stress | 3 | 2020 | 1339 | 0.140 |
Why?
| | Administration, Oral | 3 | 2013 | 848 | 0.140 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2018 | 28 | 0.130 |
Why?
| | Integrative Medicine | 1 | 2018 | 17 | 0.130 |
Why?
| | Fasting | 1 | 2019 | 277 | 0.130 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 783 | 0.130 |
Why?
| | Sugar Acids | 1 | 2017 | 4 | 0.130 |
Why?
| | Data Interpretation, Statistical | 1 | 2019 | 372 | 0.130 |
Why?
| | Hepatitis C | 1 | 2020 | 254 | 0.130 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2020 | 191 | 0.130 |
Why?
| | Antisickling Agents | 1 | 2017 | 7 | 0.130 |
Why?
| | Erythrocyte Indices | 1 | 2017 | 33 | 0.130 |
Why?
| | Injections, Intravenous | 2 | 2010 | 200 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 266 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 54 | 0.130 |
Why?
| | Hydroxyurea | 1 | 2017 | 34 | 0.130 |
Why?
| | Cross-Over Studies | 1 | 2019 | 601 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 302 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 116 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 117 | 0.130 |
Why?
| | Athletes | 1 | 2021 | 419 | 0.130 |
Why?
| | Drug Therapy, Combination | 4 | 2021 | 1048 | 0.130 |
Why?
| | Oxidoreductases | 1 | 2017 | 96 | 0.130 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8279 | 0.120 |
Why?
| | Research Design | 2 | 2019 | 1137 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 647 | 0.120 |
Why?
| | Job Application | 1 | 2016 | 17 | 0.120 |
Why?
| | In Situ Hybridization | 1 | 2016 | 319 | 0.120 |
Why?
| | Risk Factors | 5 | 2024 | 10792 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2021 | 589 | 0.120 |
Why?
| | Free Radicals | 2 | 2007 | 110 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 582 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2021 | 557 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 341 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 148 | 0.120 |
Why?
| | Respiration, Artificial | 1 | 2021 | 708 | 0.120 |
Why?
| | Stress, Mechanical | 1 | 2018 | 494 | 0.110 |
Why?
| | Hemolysis | 1 | 2017 | 243 | 0.110 |
Why?
| | Molecular Structure | 2 | 2007 | 501 | 0.110 |
Why?
| | Niacinamide | 1 | 2016 | 86 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 112 | 0.110 |
Why?
| | Prevalence | 1 | 2022 | 2836 | 0.110 |
Why?
| | Dacarbazine | 1 | 2015 | 100 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 623 | 0.110 |
Why?
| | Public Health | 1 | 2020 | 566 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1563 | 0.110 |
Why?
| | Lipids | 1 | 2020 | 710 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 4293 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 983 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2016 | 2832 | 0.110 |
Why?
| | Heparin | 1 | 2016 | 244 | 0.110 |
Why?
| | Medical Oncology | 1 | 2017 | 332 | 0.110 |
Why?
| | Collagen | 1 | 2016 | 456 | 0.100 |
Why?
| | Cell Line | 1 | 2020 | 2882 | 0.100 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2015 | 198 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2024 | 5997 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 260 | 0.100 |
Why?
| | Sleep | 1 | 2021 | 901 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 706 | 0.100 |
Why?
| | Quality of Life | 2 | 2024 | 3192 | 0.100 |
Why?
| | Stents | 1 | 2018 | 556 | 0.100 |
Why?
| | Blood Transfusion | 1 | 2017 | 405 | 0.100 |
Why?
| | Cloning, Molecular | 2 | 2013 | 541 | 0.100 |
Why?
| | Infusions, Parenteral | 2 | 2017 | 41 | 0.100 |
Why?
| | Phloretin | 1 | 2013 | 2 | 0.100 |
Why?
| | Internal Medicine | 1 | 2016 | 280 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2017 | 2499 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 7183 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 11695 | 0.090 |
Why?
| | Genotype | 1 | 2017 | 1835 | 0.090 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 224 | 0.090 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1524 | 0.090 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 372 | 0.090 |
Why?
| | Genetic Variation | 3 | 2008 | 984 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 401 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2012 | 72 | 0.090 |
Why?
| | Electrochemical Techniques | 1 | 2012 | 55 | 0.090 |
Why?
| | Adolescent | 3 | 2020 | 22453 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2016 | 324 | 0.090 |
Why?
| | Biomedical Research | 1 | 2017 | 710 | 0.080 |
Why?
| | Intestine, Small | 2 | 2010 | 166 | 0.080 |
Why?
| | Phosphorylation | 1 | 2015 | 1733 | 0.080 |
Why?
| | Anticoagulants | 1 | 2016 | 724 | 0.080 |
Why?
| | Gene Expression | 1 | 2015 | 1490 | 0.080 |
Why?
| | Placebos | 2 | 2008 | 193 | 0.080 |
Why?
| | Quinazolines | 1 | 2012 | 266 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2852 | 0.080 |
Why?
| | Protein Isoforms | 2 | 2024 | 402 | 0.080 |
Why?
| | Internship and Residency | 2 | 2016 | 1257 | 0.080 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 588 | 0.080 |
Why?
| | Histones | 1 | 2015 | 670 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1786 | 0.080 |
Why?
| | Glucose Transporter Type 5 | 2 | 2006 | 4 | 0.080 |
Why?
| | Glutathione Transferase | 1 | 2009 | 100 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 205 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2016 | 783 | 0.070 |
Why?
| | Diet | 2 | 2017 | 1275 | 0.070 |
Why?
| | Cell Growth Processes | 1 | 2009 | 50 | 0.070 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 244 | 0.070 |
Why?
| | Carcinoma | 1 | 2011 | 228 | 0.070 |
Why?
| | Exercise | 2 | 2016 | 2201 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2016 | 4155 | 0.070 |
Why?
| | Phenotype | 1 | 2017 | 3164 | 0.070 |
Why?
| | Survival Analysis | 2 | 2016 | 1385 | 0.070 |
Why?
| | Therapeutic Human Experimentation | 1 | 2008 | 1 | 0.070 |
Why?
| | Patient Isolation | 1 | 2008 | 20 | 0.070 |
Why?
| | Ethics, Research | 1 | 2008 | 32 | 0.070 |
Why?
| | Blood Preservation | 1 | 2012 | 354 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2019 | 405 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1465 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 735 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 635 | 0.070 |
Why?
| | Vitamin D Deficiency | 1 | 2009 | 186 | 0.070 |
Why?
| | Truth Disclosure | 1 | 2008 | 50 | 0.070 |
Why?
| | Oxygen | 1 | 2013 | 995 | 0.070 |
Why?
| | Animals, Newborn | 1 | 2010 | 902 | 0.060 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2006 | 11 | 0.060 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1462 | 0.060 |
Why?
| | Caco-2 Cells | 1 | 2006 | 79 | 0.060 |
Why?
| | Flavonols | 1 | 2006 | 26 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3082 | 0.060 |
Why?
| | Trust | 1 | 2008 | 153 | 0.060 |
Why?
| | Microscopy, Confocal | 1 | 2006 | 321 | 0.060 |
Why?
| | Adenoma | 1 | 2008 | 218 | 0.060 |
Why?
| | Pregnancy | 3 | 2022 | 7191 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2008 | 612 | 0.050 |
Why?
| | Poly A | 1 | 2004 | 50 | 0.050 |
Why?
| | Phosphoramide Mustards | 1 | 2024 | 4 | 0.050 |
Why?
| | Nitrogen Mustard Compounds | 1 | 2024 | 9 | 0.050 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2004 | 97 | 0.050 |
Why?
| | A549 Cells | 1 | 2024 | 75 | 0.050 |
Why?
| | Actin Cytoskeleton | 1 | 2024 | 103 | 0.050 |
Why?
| | Cardiovascular Diseases | 2 | 2009 | 2171 | 0.050 |
Why?
| | Sex Characteristics | 1 | 2009 | 791 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1054 | 0.050 |
Why?
| | Curriculum | 2 | 2021 | 1060 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2024 | 2157 | 0.050 |
Why?
| | Cytoskeleton | 1 | 2024 | 195 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2024 | 247 | 0.050 |
Why?
| | L-Gulonolactone Oxidase | 1 | 2022 | 2 | 0.050 |
Why?
| | Transfection | 2 | 2002 | 940 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2010 | 931 | 0.050 |
Why?
| | Child | 1 | 2023 | 22657 | 0.050 |
Why?
| | Prostatic Neoplasms | 1 | 2010 | 978 | 0.050 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 160 | 0.050 |
Why?
| | Erythropoiesis | 1 | 2022 | 57 | 0.050 |
Why?
| | Reference Values | 1 | 2004 | 798 | 0.050 |
Why?
| | Rats, Zucker | 1 | 2002 | 32 | 0.050 |
Why?
| | Prospective Studies | 3 | 2019 | 7997 | 0.040 |
Why?
| | Fruit | 1 | 2003 | 152 | 0.040 |
Why?
| | CHO Cells | 1 | 2002 | 171 | 0.040 |
Why?
| | Vegetables | 1 | 2003 | 170 | 0.040 |
Why?
| | Deoxyglucose | 1 | 2002 | 51 | 0.040 |
Why?
| | Premature Birth | 1 | 2005 | 380 | 0.040 |
Why?
| | Cricetinae | 1 | 2002 | 304 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2022 | 215 | 0.040 |
Why?
| | Area Under Curve | 1 | 2022 | 331 | 0.040 |
Why?
| | Intestinal Absorption | 1 | 2002 | 103 | 0.040 |
Why?
| | Erythrocyte Count | 1 | 2021 | 21 | 0.040 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 18 | 0.040 |
Why?
| | Genes, Reporter | 1 | 2002 | 276 | 0.040 |
Why?
| | Credentialing | 1 | 2021 | 21 | 0.040 |
Why?
| | Humanities | 1 | 2021 | 8 | 0.040 |
Why?
| | Diet Therapy | 1 | 2021 | 37 | 0.040 |
Why?
| | Hematocrit | 1 | 2021 | 108 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 53 | 0.040 |
Why?
| | Health Occupations | 1 | 2021 | 36 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2025 | 897 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2007 | 947 | 0.040 |
Why?
| | Vasoconstrictor Agents | 1 | 2021 | 144 | 0.040 |
Why?
| | Lipogenesis | 1 | 2020 | 62 | 0.040 |
Why?
| | Morals | 1 | 2021 | 80 | 0.040 |
Why?
| | Policy | 1 | 2021 | 147 | 0.040 |
Why?
| | Spirochaetales | 1 | 2019 | 1 | 0.040 |
Why?
| | Phylogeny | 1 | 2004 | 1019 | 0.040 |
Why?
| | Endocardium | 1 | 2019 | 31 | 0.040 |
Why?
| | 5-Methylcytosine | 1 | 2020 | 25 | 0.040 |
Why?
| | Granzymes | 1 | 2020 | 49 | 0.040 |
Why?
| | Borrelia burgdorferi | 1 | 2019 | 21 | 0.040 |
Why?
| | Alleles | 2 | 2017 | 881 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2008 | 848 | 0.040 |
Why?
| | Heart Block | 1 | 2019 | 40 | 0.040 |
Why?
| | Signal Transduction | 1 | 2013 | 5233 | 0.040 |
Why?
| | Atrioventricular Block | 1 | 2019 | 45 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4569 | 0.040 |
Why?
| | Massachusetts | 1 | 2019 | 180 | 0.040 |
Why?
| | Paraganglioma | 1 | 2020 | 65 | 0.040 |
Why?
| | Fibroblasts | 1 | 2004 | 1034 | 0.040 |
Why?
| | Models, Biological | 1 | 2006 | 1822 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 336 | 0.040 |
Why?
| | Counseling | 1 | 2002 | 408 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2019 | 307 | 0.040 |
Why?
| | Neutrophils | 1 | 2004 | 1134 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 965 | 0.040 |
Why?
| | Perioperative Care | 1 | 2021 | 231 | 0.040 |
Why?
| | Teaching | 1 | 2021 | 236 | 0.030 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 271 | 0.030 |
Why?
| | Manitoba | 1 | 2017 | 4 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2020 | 245 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 264 | 0.030 |
Why?
| | Xenopus | 1 | 2017 | 89 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 241 | 0.030 |
Why?
| | Up-Regulation | 1 | 2020 | 852 | 0.030 |
Why?
| | Anesthesia | 1 | 2021 | 258 | 0.030 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2017 | 334 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2020 | 1253 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2005 | 1241 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2010 | 2642 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1098 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3676 | 0.030 |
Why?
| | Electrocardiography | 1 | 2019 | 663 | 0.030 |
Why?
| | DNA | 1 | 2003 | 1464 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2017 | 919 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 732 | 0.030 |
Why?
| | Health Promotion | 1 | 2002 | 774 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2016 | 174 | 0.030 |
Why?
| | Haplotypes | 2 | 2008 | 490 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1337 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 657 | 0.030 |
Why?
| | Critical Illness | 1 | 2021 | 892 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2019 | 1031 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2020 | 917 | 0.020 |
Why?
| | Precision Medicine | 1 | 2017 | 458 | 0.020 |
Why?
| | Firearms | 1 | 2020 | 435 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2925 | 0.020 |
Why?
| | Clinical Competence | 1 | 2021 | 1244 | 0.020 |
Why?
| | Patient Selection | 1 | 2016 | 719 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 194 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2010 | 252 | 0.020 |
Why?
| | Brain | 1 | 2002 | 2941 | 0.020 |
Why?
| | Mitochondria | 1 | 2016 | 984 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2010 | 334 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2010 | 451 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2365 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 4099 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2021 | 2920 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2010 | 381 | 0.020 |
Why?
| | Disease Notification | 1 | 2008 | 16 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5417 | 0.020 |
Why?
| | American Medical Association | 1 | 2008 | 19 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 615 | 0.020 |
Why?
| | Placebo Effect | 1 | 2008 | 25 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5965 | 0.020 |
Why?
| | Community Participation | 1 | 2008 | 132 | 0.020 |
Why?
| | Informed Consent | 1 | 2008 | 198 | 0.010 |
Why?
| | Body Weight | 1 | 2010 | 978 | 0.010 |
Why?
| | North Carolina | 1 | 2005 | 128 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2011 | 883 | 0.010 |
Why?
| | Forearm | 1 | 2005 | 140 | 0.010 |
Why?
| | Glucose Clamp Technique | 1 | 2005 | 199 | 0.010 |
Why?
| | Gene Components | 1 | 2004 | 6 | 0.010 |
Why?
| | Base Composition | 1 | 2004 | 82 | 0.010 |
Why?
| | Likelihood Functions | 1 | 2004 | 143 | 0.010 |
Why?
| | Linkage Disequilibrium | 1 | 2004 | 247 | 0.010 |
Why?
| | Species Specificity | 1 | 2004 | 574 | 0.010 |
Why?
| | Genomic Library | 1 | 2002 | 17 | 0.010 |
Why?
| | Restriction Mapping | 1 | 2002 | 80 | 0.010 |
Why?
| | Surveys and Questionnaires | 2 | 2008 | 6053 | 0.010 |
Why?
| | Genes, Essential | 1 | 2002 | 21 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2002 | 204 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.010 |
Why?
| | Vasodilation | 1 | 2005 | 523 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2002 | 277 | 0.010 |
Why?
| | Models, Genetic | 1 | 2004 | 536 | 0.010 |
Why?
| | Testis | 1 | 2002 | 163 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2002 | 151 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2004 | 824 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2191 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1769 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2931 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1186 | 0.010 |
Why?
|
|
Levine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|